The iconic rise of Viagra has consistently remained a symbol of pharmaceutical success, but its legacy within the broader market now triggers questions about potential returns . Copycat versions are eroding patent protection , leading to anxieties that investing in companies significantly dependent to Viagra's previous standing could be a dangerous